DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, is presenting the results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Titled “Impact of Digital Intervention Engine on Diabetes Self-Management,” the study analyzes personalized digital interventions and the impact they have on clinical and engagement outcomes; specifically, the study examined the impact of DRIO’s highly personalized digital journeys, including applying user-specific digital intervention flows for behavioral change to increase user digital engagement. The student involved 246 DarioHealth users. Highlights of the study include the percentage of users who measured blood glucose being significantly higher in the test group of Dario users, which received interventions driven by the digital intervention engine — 14% in first 30 days and 22% in 30 to 60 days — and the average number of blood glucose measurements increased by 6% and 17% at first 30 days and 30 to 60 days, respectively. In addition, the average number of days between blood glucose measurements, known as recency, was significantly improved by 30% in the test group. The conference is being held June 2–5, 2021. “The potential benefit of this research could be life-changing for so many people,” said DarioHealth scientific and clinical director Dr. Yifat Hershcovitz, PhD., in the press release. “In the context of busy day-to-day life, simply remembering to perform blood glucose measurements at meaningful intervals may be a challenge. The results of this study confirm that DarioHealth’s platform and hyper-personalized approach makes it much easier for people to remember to incorporate measuring glucose levels into their everyday lives, improving and maintaining health outcomes.”
To view the full press release, visit https://ibn.fm/NQZ3S
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.